- Home
- CMDB vs EDIT Comparison
CMDB vs EDIT Comparison
Compare CMDB & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMDB | EDIT |
|---|---|---|
| Founded | 2023 | 2013 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.4M | 432.8M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | CMDB | EDIT |
|---|---|---|
| Price | $17.47 | $2.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.30 |
| AVG Volume (30 Days) | 41.9K | ★ 2.7M |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $8.46 | $1.66 |
| 52 Week High | $19.93 | $4.54 |
Technical Indicators
Market Signals| Indicator | CMDB | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 53.32 | 51.01 |
| Support Level | $16.18 | $2.77 |
| Resistance Level | $17.71 | $3.27 |
| Average True Range (ATR) | 0.80 | 0.20 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 63.28 | 70.16 |
Price Performance
Historical ComparisonAbout CMDB Costamare Bulkers Holdings Limited
Costamare Bulkers Holdings Ltd is an international owner and operator of dry bulk vessels providing transportation of dry bulk commodities globally for a broad range of customers. Its vessels transport a broad range of bulks, such as iron ore, coal and grains and minor bulks, such as bauxite, phosphate fertilizers and steel products, across shipping routes globally. The company's vessel fleet includes Current Dry Bulk Fleet, Chartered-In Vessels Fleet, and Chartered-In Newbuilding Vessels. It operates under one reportable segment, that of operating dry bulk vessels.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.